Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/3070% below fair value
$2.66+0.84 (+46.15%)
Close on Nov 17, 2026Market cap $28.91MP/E –Yield –
Earnings
Aytu BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 12, 2026
Q1 FY2027 · estimated, during market hours
Revenue, Q4 FY2026
$16.10M
+6.6% on a year earlier
EPS, Q4 FY2026
$0.00
-$2.92 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Aytu BioPharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q1 FY2027ended Sep 30, 2026 | Nov 12, 2026Expected | – | – | – | – |
| Q4 FY2026ended Jun 30, 2026 | Sep 22, 2026during market hours | $16.10M | +6.6% | $0.00 | Release |
| Q3 FY2026ended Mar 31, 2026 | May 13, 2026during market hours | $12.40M | -33.0% | -$0.53 | Release |
| Q2 FY2026ended Dec 31, 2025 | Feb 3, 2026during market hours | $15.20M | -6.2% | -$1.05 | Release |
| Q1 FY2026ended Sep 30, 2025 | Nov 13, 2025during market hours | $13.90M | -16.3% | -$0.08 | Release |
| Q4 FY2025ended Jun 30, 2025 | Sep 23, 2025during market hours | $15.10M | -16.1% | -$2.92 | Release |
| Q3 FY2025ended Mar 31, 2025 | May 14, 2025during market hours | $18.50M | +2.8% | $0.21 | Release |
| Q2 FY2025ended Dec 31, 2024 | Feb 12, 2025during market hours | $16.20M | -29.3% | -$0.26 | Release |
| Q1 FY2025ended Sep 30, 2024 | Nov 13, 2024during market hours | $16.60M | -24.9% | -$0.15 | Release |
| Q4 FY2024ended Jun 30, 2024 | Sep 26, 2024during market hours | $18.00M | -41.4% | -$0.82 | Release |
| Q3 FY2024ended Mar 31, 2024 | May 15, 2024during market hours | $18.00M | -20.7% | -$0.52 | Release |
| Q2 FY2024ended Dec 31, 2023 | Feb 14, 2024during market hours | $22.90M | -12.9% | -$0.04 | Release |
| Q1 FY2024ended Sep 30, 2023 | Nov 14, 2023during market hours | $22.10M | -20.2% | -$1.48 | Release |
| Q4 FY2023ended Jun 30, 2023 | Sep 27, 2023during market hours | $30.70M | +12.0% | -$0.59 | Release |
| Q3 FY2023ended Mar 31, 2023 | May 11, 2023during market hours | $22.70M | -6.2% | -$1.93 | Release |
| Q2 FY2023ended Dec 31, 2022 | Feb 21, 2023during market hours | $26.30M | +13.9% | -$2.15 | Release |
| Q1 FY2023ended Sep 30, 2022 | Nov 14, 2022during market hours | $27.70M | +26.5% | -$0.06 | Release |
| Q4 FY2022ended Jun 30, 2022 | Sep 28, 2022during market hours | $27.40M | – | -$0.49 | Release |
| Q3 FY2022ended Mar 31, 2022 | May 16, 2022during market hours | $24.20M | – | -$1.79 | Release |
| Q2 FY2022ended Dec 31, 2021 | Feb 14, 2022during market hours | $23.10M | – | -$0.44 | Release |
| Q1 FY2022ended Sep 30, 2021 | Nov 15, 2021during market hours | $21.90M | – | -$1.09 | Release |
| Q4 FY2021ended Jun 30, 2021 | Sep 27, 2021during market hours | – | – | – | Filing |
| Q3 FY2021ended Mar 31, 2021 | May 17, 2021during market hours | – | – | – | Filing |
| Q2 FY2021ended Dec 31, 2020 | Feb 11, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Sep 30, 2020 | Oct 6, 2020during market hours | – | – | – | Filing |
| Q3 FY2020ended Mar 31, 2020 | May 7, 2020before the open | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Aytu BioPharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Aytu BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Aytu BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Update
- Update
- Update
- Update
- Results
See a number that looks wrong?